Search

Your search keyword '"Lahner H"' showing total 175 results
Start Over Author "Lahner H"
175 results on '"Lahner H"'

6. Neuroendokrine Neoplasien der Mamma

Author

Anlauf, M., Neumann, M., Bomberg, S., Luczak, K., Heikaus, S., Gustmann, C., Antke, C., Ezziddin, S., Fottner, C., Pavel, M., Pape, U.-F., Rinke, A., Lahner, H., Schott, M., Cremer, B., Hörsch, D., Baum, R.P., Groh, U., Alkatout, I., Rudlowski, C., Scheler, P., Zirbes, T.K., Hoffmann, J., Fehm, T., Gabbert, H.E., and Baldus, S.E.

Published
2015
Full Text
View/download PDF

7. Neuroendokrine Neoplasien des distalen Jejunums und Ileums

Author

Anlauf, M., Sipos, B., Boeck, I., Baldus, S.E., Heikaus, S., Krausch, M., Knoefel, W.T., Begum, N., Goretzki, P., Schott, M., Auernhammer, C.J., Cremer, B., Rinke, A., Ezziddin, S., Fottner, C., Pöpperl, G., Lahner, H., Hörsch, D., Gabbert, H.E., Komminoth, P., Perren, A., Klöppel, G., Wiedenmann, B., Pavel, M., and Pape, U.

Published
2014
Full Text
View/download PDF

10. The Effect of Pegvisomant on Cardiovascular Risk in Patients with Active Acromegaly in Comparison to Matched Data from the General Population.

Author

Berg, C, primary, Petersenn, S, additional, Lahner, H, additional, Herrmann, BL, additional, Buchfelder, M, additional, Droste, M, additional, Stalla, GK, additional, Strasburger, CJ, additional, Roggenbuck, U, additional, Lehmann, N, additional, Moebus, S, additional, Jockel, KH, additional, Moehlenkamp, S, additional, Erbel, R, additional, Saller, B, additional, and Mann, K, additional

Published
2010
Full Text
View/download PDF

15. [Somatostatin receptor PET/CT (SSTR-PET/CT)]

Author

Boy, C., Poeppel, T., Kotzerke, J., Krause, B.J., Amthauer, H., Baum, R.P., Buchmann, I., Ezziddin, S., Fuhrer, D., Gabriel, M., Kuwert, T., Lahner, H., Lauenstein, T., Maecke, H.R., Nagarajah, J., Rosch, F., Scheidhauer, K., Schmidt, M., Walter, M.A., and Bockisch, A.

Subjects
Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]
Abstract

Item does not contain fulltext The present guideline is focused on quality assurance of somatostatin receptor PET/CT (SSTR-PET/CT) in oncology patients. The document has been developed by a multidisciplinary board of specialists providing consensus of definitions, prerequisites, methodology, operating procedures, assessment, and standardized reporting. In particular, imaging procedures for the two most commonly used radioligands of human SSTR, i. e. 68Ga-DOTATOC and 68Ga-DOTATATE are presented. Overall, SSTR-PET/CT requires close interdisciplinary communication and cooperation of referring and executing medical disciplines, taking into account existing guidelines and recommendations of the European and German medical societies, including the European Association of Nuclear Medicine (EANM), German Society for Endocrinology (DGE), German Society for Nuclear Medicine (DGN) and German Society for Radiology (DRG).

Published
2018

18. Somatostatinrezeptor-PET/CT

Author

Boy, C., primary, Poeppel, T., primary, Kotzerke, J., primary, Krause, B. J., primary, Amthauer, H., primary, Baum, R. P., primary, Buchmann, I., primary, Ezziddin, S., primary, Führer, D., primary, Gabriel, M., primary, Kuwert, T., primary, Lahner, H., primary, Lauenstein, T., primary, Maecke, H. R., primary, Nagarajah, J., primary, Rösch, F., primary, Scheidhauer, K., primary, Schmidt, M., primary, Walter, M. A., primary, and Bockisch, A., primary

Published
2018
Full Text
View/download PDF

19. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

Author

nicola fazio, Buzzoni, R., Baudin, E., Antonuzzo, L., Hubner, R. A., Lahner, H., Herder, W. W., Raderer, M., Teulé, A., Capdevila, J., Libutti, S. K., Kulke, M. H., Shah, M., Dey, D., Turri, S., Aimone, P., Massacesi, C., Verslype, C., and Internal Medicine

Subjects
Adult, Aged, 80 and over, Male, Time Factors, TOR Serine-Threonine Kinases, Medizin, Imidazoles, Administration, Oral, Antineoplastic Agents, Middle Aged, Article, Drug Administration Schedule, Pancreatic Neoplasms, Neuroendocrine Tumors, Treatment Outcome, Drug Resistance, Neoplasm, Quinolines, Humans, Female, Everolimus, Prospective Studies, Phosphatidylinositol 3-Kinase, Protein Kinase Inhibitors, Aged, Phosphoinositide-3 Kinase Inhibitors
Abstract

This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436).In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progression-free survival (PFS) rate of ≥60% in stage 1.As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7%) patients at 400 mg and eight (40.0%) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6% (90% confidence interval=35.7-67.3%).BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2.

Published
2016

20. [Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]

Author

Td, Poeppel, Boy C, Bockisch A, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Bj, Krause, Schmidt D, Amthauer H, Rösch F, Nagarajah J, Führer D, Lahner H, Pöpperl G, Hörsch D, Martin A. Walter, and Rp, Baum

Subjects
Germany, Neoplasms, Practice Guidelines as Topic, Radiation Oncology, Humans, Receptors, Somatostatin, Radiopharmaceuticals, Peptides
Abstract

This document describes the guideline for peptide receptor radionuclide therapy (PRRT) published by the German Society of Nuclear Medicine (DGN) and accepted by the Association of the Scientific Medical Societies in Germany (AWMF) to be included in the official AWMF Guideline Registry. These recommendations are a prerequisite for the quality management in the treatment of patients with somatostatin receptor expressing tumours using PRRT. They are aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRT and to deliver the treatment in a safe and effective manner. The recommendations are based on an interdisciplinary consensus. The document contains background information and definitions and covers the rationale, indications and contraindications for PRRT. Essential topics are the requirements for institutions performing the therapy, e. g. presence of an expert for medical physics, intense cooperation with all colleagues involved in the treatment of a patient, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how treatment has to be carried out technically. Here, quality control and documentation of labelling are of great importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with the involved medical disciplines. Generally, the decision for PRRT should be undertaken within the framework of a multi-disciplinary tumour board.

Published
2014

23. 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

Author

Yao, J., primary, Fazio, N., additional, Singh, S., additional, Buzzoni, R., additional, Carnaghi, C., additional, Wolin, E., additional, Tomasek, J., additional, Raderer, M., additional, Lahner, H., additional, Voi, M., additional, Pacaud, L., additional, Lincy, J., additional, Sachs, C., additional, Valle, J., additional, Delle Fave, G., additional, Van Cutsem, E., additional, Tesselaar, M.E.T., additional, Shimada, Y., additional, Oh, D.Y., additional, Strosberg, J., additional, Kulke, M.H., additional, and Pavel, M.E., additional

Published
2015
Full Text
View/download PDF

30. Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor- exprimierender Tumore

Author

Boy, C., primary, Bockisch, A., primary, Kotzerke, J., primary, Buchmann, I., primary, Ezziddin, S., primary, Scheidhauer, K., primary, Krause, B. J., primary, Schmidt, D., primary, Amthauer, H., primary, Rösch, F., primary, Nagarajah, J., primary, Führer, D., primary, Lahner, H., primary, Pöpperl, G., primary, Hörsch, D., primary, Walter, M. A., primary, Baum, R. P., primary, and Poeppel, T. D., additional

Published
2015
Full Text
View/download PDF

31. Neuroendocrine neoplasms of the distal jejunum and ileum

Author

Anlauf, M., Sipos, B., Boeck, I., Baldus, S. E., Heikaus, S., Krausch, M., Knoefel, W. T., Begum, N., Goretzki, P., Schott, M., Auernhammer, C. J., Cremer, B., Rinke, A., Ezziddin, S., Fottner, C., Poepperl, G., Lahner, H., Hoersch, D., Gabbert, H. E., Komminoth, P., Perren, A., Kloeppel, G., Wiedenmann, B., Pavel, M., Pape, U., Anlauf, M., Sipos, B., Boeck, I., Baldus, S. E., Heikaus, S., Krausch, M., Knoefel, W. T., Begum, N., Goretzki, P., Schott, M., Auernhammer, C. J., Cremer, B., Rinke, A., Ezziddin, S., Fottner, C., Poepperl, G., Lahner, H., Hoersch, D., Gabbert, H. E., Komminoth, P., Perren, A., Kloeppel, G., Wiedenmann, B., Pavel, M., and Pape, U.

Abstract

Neuroendocrine neoplasms (NEN) of the distal jejunum and ileum derive from serotonin-producing enterochromaffin (EC) cells. Due to their low proliferation rate and their infiltrative growth, they are often discovered at an advanced disease stage when metastasis has already occurred. The biology of these tumours is different from other NEN of the digestive tract. In order to standardise and improve diagnosis and therapy, the guidelines for the diagnosis and clinical management of jejuno-ileal NEN as well as for the management of patients with liver and other distant metastases from NEN were revised by the European Neuroendocrine Tumour Society (ENETS) in 2012. This review focuses on aspects relevant for surgical pathology.

Published
2014

32. Ph Ii Study of Bez235 in Patients with Advanced Pancreatic Neuroendocrine Tumors (Pnet) After Mtor Inhibitor Therapy Failure: Stage I Interim Results

Author

Fazio, N., primary, Buzzoni, R., additional, Baudin, E., additional, Antonuzzo, L., additional, Hubner, R., additional, Lahner, H., additional, De Herder, W.W., additional, Raderer, M., additional, Teule, A., additional, Capdevila, J., additional, Libutti, S., additional, Kulke, M., additional, Shah, M., additional, Dey, D., additional, Turri, S., additional, Aimone, P., additional, and Verslype, C., additional

Published
2014
Full Text
View/download PDF

50. OR3,14 The influence of IGF-I normalization on cardiovascular risk in patients with uncontrolled and long-term acromegaly in comparison to matched data from the general population

Author

Berg, C., primary, Petersenn, S., additional, Lahner, H., additional, Herrmann, B., additional, Buchfelder, M., additional, Droste, M., additional, Stalla, G.K., additional, Strasburger, C.J., additional, Roggenbuck, U., additional, Lehmann, N., additional, Moebus, S., additional, Jöckel, K.-H., additional, Möhlenkamp, S., additional, Erbel, R., additional, Saller, B., additional, and Mann, K., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results